EirGenix Looks For Partner As Pertuzumab Passes Phase I
Developer Is Negotiating With Firms Ahead Of Planned Global Launch Of Perjeta Biosimilar
With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.
